SARDH

Chr 9AR

sarcosine dehydrogenase

Also known as: BPR-2, DMGDHL1, SAR, SARD, SDH

The protein catalyzes the conversion of sarcosine to glycine in the final step of choline degradation to glycine. Autosomal recessive mutations cause sarcosinemia, a metabolic disorder affecting amino acid metabolism. This gene is not highly constrained against loss-of-function variants, consistent with the generally benign nature of sarcosinemia in most affected individuals.

GeneReviewsOMIMResearchSummary from OMIM, UniProt
MultiplemechanismARLOEUF 0.881 OMIM phenotype
Clinical SummarySARDH
🧬
Gene-Disease Validity (ClinGen)
sarcosinemia · ARLimited

Limited evidence — not for standalone diagnostic reporting

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
31 unique Pathogenic / Likely Pathogenic· 111 VUS of 189 total submissions
💊
Clinical Trials
1 active or recruiting trial — potential therapeutic options may be available
📖
GeneReview available — SARDH
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.88LOEUF
pLI 0.000
Z-score 2.23
OE 0.66 (0.490.88)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.68Z-score
OE missense 0.92 (0.860.99)
561 obs / 608.1 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.66 (0.490.88)
00.351.4
Missense OE0.92 (0.860.99)
00.61.4
Synonymous OE0.99
01.21.6
LoF obs/exp: 32 / 48.8Missense obs/exp: 561 / 608.1Syn Z: 0.10
DN
0.6841th %ile
GOF
0.73top 25%
LOF
0.3550th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

189 submitted variants in ClinVar

Classification Summary

Pathogenic29
Likely Pathogenic2
VUS111
Likely Benign12
Benign15
29
Pathogenic
2
Likely Pathogenic
111
VUS
12
Likely Benign
15
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
1
0
28
0
29
Likely Pathogenic
1
0
1
0
2
VUS
0
105
6
0
111
Likely Benign
0
7
1
4
12
Benign
0
5
1
9
15
Total21173713169

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

SARDH · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold
Clinical Literature
Open Research Assistant →